Go have a look at the last paragraph of lead investigator ...... with 9/10 ventilated patients not making it “preventing or delaying their progression to ventilation and IC” ....... this alone may be a godsend to many
Preclinical trial data seems to have convinced both 4d and MRA that there is significant chance of efficacy .... even the professor heading the Oxford Virology vaccine effort was unable to guide on length of immunity and as with flu etc vaccination profiles may need to change as the virus spreads and continues its lifecycle .... seems that we will be living with Covid worldwide do to have a treatment that can enable the body to buy time and fight from within will be worthy of 1-2 billion therapies over the next 3-5 years .... wonder if Merck are brushing off their NED’s to see if it’s worth a punt
Likely someone’s a position to protect before the mms let it run away !!!! Once the analysts look at the news release in Trumptown will see a 2.30 foot race IMHO
Money in the bank , Merck holding stock , a number of ongoing trials in +ve territory and now a possible Covid 19 immuno suppressive therapy .... looks like a terser is due
Have had a number of recent revisions alongside an increased product depth .... likely signifies increased specific orders .... This is good news as likely the Murata lines will be set on prismatic production with cap-xx heritage on cylindrical .... 3v prismatic set for 3 rd qtr 2020 when Murata lines fully operational so we should see a significant number of new income streams in 20-21
Tesla Battery team will no doubt have done some work but unless it’s radical others will be catching up !! I hear the Williams team have done exciting work ongoing which they will sell on... best if Elon gets his credit card out before Geeley do IMHO
Super cap ?? Maxwells been in the fold for 6 months so should see some integration within a Tesla soon.... think that will set a precedent that cap-xx would welcome